Cette page a été traduite automatiquement et l'exactitude de la traduction n'est pas garantie. Veuillez vous référer au version anglaise pour un texte source.

Système de diagnostic et de surveillance basé sur les biomarqueurs urinaires pour la maladie rénale chronique et efficacité réelle des inhibiteurs du SGLT2

Système de diagnostic et de surveillance de la maladie rénale chronique basé sur les biomarqueurs urinaires et traitement préventif avec l'inhibiteur du SGLT2, l'empagliflozine

This prospective observational study aims to assess the association between real-world use of sodium-glucose co-transporter 2 inhibitors (SGLT2i; e.g., empagliflozin, dapagliflozin) and renal function decline in adults with chronic kidney disease (CKD) stages 2-4 (KDIGO classification). The study will also validate a urinary biomarker panel for early diagnosis and monitoring of CKD progression.

No investigational product is assigned, and medical practice or prescription patterns are not altered.

Aperçu de l'étude

Statut

Recrutement

Les conditions

Intervention / Traitement

Description détaillée

This is a real-world, observational study with prospective follow-up and retrospective baseline data when available, conducted at the Nephrology Department of the University Hospital of Salamanca, Spain.

The project integrates translational and clinical components:

  1. validation of a urinary biomarker panel obtained through differential proteomics for early detection and monitoring of CKD progression, and
  2. evaluation of the effectiveness and safety of SGLT2i in routine clinical practice.

A total of 300 adults with CKD stages 2-4 will be included (150 initiating SGLT2i and 150 matched controls). Participants will be followed for 12 months (baseline, 6, and 12 months). Data will be extracted exclusively from electronic health records and laboratory systems.

The primary outcome is the annual decline rate of estimated glomerular filtration rate (eGFR, CKD-EPI 2021). Secondary outcomes include a composite renal endpoint (≥40% sustained eGFR decline, renal replacement therapy, transplantation, or renal death), cardiovascular hospitalization, all-cause mortality, adverse drug reactions (ADRs), and real-world patterns of SGLT2i use.

Exploratory analyses will assess associations between urinary biomarkers and clinical outcomes.

The study follows Spanish regulations for observational studies with medicinal products (Real Decreto 957/2020), with ethics approval and informed consent for biological samples.

Type d'étude

Observationnel

Inscription (Estimé)

300

Contacts et emplacements

Cette section fournit les coordonnées de ceux qui mènent l'étude et des informations sur le lieu où cette étude est menée.

Coordonnées de l'étude

  • Nom: Carlos Martínez Salgado, PhD
  • Numéro de téléphone: +34616129633
  • E-mail: carlosms@usal.es

Lieux d'étude

      • Salamanca, Espagne
        • Recrutement
        • Hospital Universitario de Salamanca
        • Contact:
          • Carlos Martínez Salgado, PhD
          • Numéro de téléphone: +34616129633
          • E-mail: carlosms@usal.es
        • Contact:
          • Pilar Fraile Gómez, MD, PhD
          • Numéro de téléphone: +34923291100
          • E-mail: pilarfg@usal.es

Critères de participation

Les chercheurs recherchent des personnes qui correspondent à une certaine description, appelée critères d'éligibilité. Certains exemples de ces critères sont l'état de santé général d'une personne ou des traitements antérieurs.

Critère d'éligibilité

Âges éligibles pour étudier

16 ans et plus (Enfant, Adulte, Adulte plus âgé)

Accepte les volontaires sains

Non

Sexes éligibles pour l'étude

Tout

Méthode d'échantillonnage

Échantillon de probabilité

Population étudiée

Participants with chronic kidney disease (CKD) stages 2-4.

La description

Inclusion Criteria:

  • ≥18 years old
  • Diagnosed with chronic kidney disease (KDIGO stages 2-4)
  • Life expectancy ≥12 months
  • Available clinical and laboratory data in the electronic medical record

Exclusion Criteria:

  • Current or recent renal replacement therapy or kidney transplantation
  • End-stage renal disease
  • Participation in interventional trials that may affect outcomes
  • Allergy or intolerance to SGLT2i (for exposed cohort)

Plan d'étude

Cette section fournit des détails sur le plan d'étude, y compris la façon dont l'étude est conçue et ce que l'étude mesure.

Comment l'étude est-elle conçue ?

Détails de conception

  • Modèles d'observation: COHORT
  • Perspectives temporelles: PROSPECTIVE

Cohortes et interventions

Groupe / Cohorte
Intervention / Traitement
Empagliflozin Treatment Group

Participants with chronic kidney disease (CKD) stages 2-4 will receive oral empagliflozin (10-25 mg daily) for 12 months. Urinary and plasma samples will be collected at baseline, 6 months, and 12 months to evaluate the urinary biomarker panel, renal function (eGFR), and treatment safety.

Oral empagliflozin (10-25 mg daily) for 12 months

Control group

Adults with chronic kidney disease (CKD) stages 2-4 (KDIGO classification) managed in nephrology outpatient clinics without initiation of SGLT2 inhibitors at baseline or during follow-up.

These patients receive standard clinical care according to local and national guidelines.

They are followed on the same schedule (baseline, 6, and 12 months) and have identical variables collected from electronic health records and laboratory systems.

Reasons for non-initiation of SGLT2i are documented systematically and may include:

Not meeting indication criteria established by the Spanish National Health System (e.g., albumin-to-creatinine ratio <200 mg/g, eGFR <20 mL/min/1.73 m² for empagliflozin or <25 for dapagliflozin), or

Clinical contraindications or conditions such as significant hypovolemia or hypotension, recurrent urinary or genital infections, or hypersensitivity.

Control patients will be censored in the primary analysis if they later start SGLT2i therapy (cross-over).

Que mesure l'étude ?

Principaux critères de jugement

Mesure des résultats
Description de la mesure
Délai
Change in urinary biomarker panel expression (proteomic fingerprint)
Délai: Baseline, 6 months, 12 months

Quantitative assessment of urinary biomarkers (including KIM-1, transferrin, IGFBP7, TIMP-2, among others) to evaluate disease progression and treatment response. Urinary biomarkers will be assessed using liquid chromatography-mass spectrometry (LC-MS/MS)-based differential proteomic analysis. Biomarker expression will be quantified as log2 fold change with false discovery rate (FDR) correction. Selected biomarkers will be validated using enzyme-linked immunosorbent assay (ELISA) or equivalent immunoassays. Biomarker concentrations will be normalized to urinary creatinine levels.

Baseline, 6 months, 12 months

Mesures de résultats secondaires

Mesure des résultats
Description de la mesure
Délai
Change in estimated glomerular filtration rate (eGFR)
Délai: Baseline, 6 months, 12 months

Evaluation of renal function improvement or stabilization during SGLT2 inhibitor treatment.

Baseline, 6 months, 12 months
Histopathological improvement of renal tissue (animal study)
Délai: Monthly up to 9 months

Monthly analysis of renal fibrosis, inflammation, and extracellular matrix accumulation in preclinical models treated with empagliflozin.

Monthly up to 9 months
Monitoring of adverse events of empagliflozin in CKD patients without diabetes
Délai: From baseline to 12 months

Adverse events (AEs) will be recorded and classified according to Common Terminology Criteria for Adverse Events (CTCAE, latest version), including severity grading and assessment of causality related to treatment.

Serious adverse events (SAEs) and discontinuations due to AEs will be specifically tracked by the investigator.

From baseline to 12 months
Change in estimated glomerular filtration rate (eGFR)
Délai: From baseline to 12 months

Change in renal function assessed by estimated glomerular filtration rate (eGFR) calculated using the CKD-EPI equation during empagliflozin treatment using the Serum creatinine-based CKD-EPI equation.

From baseline to 12 months
Change in serum creatinine
Délai: From baselinte to 12 months

hange in serum creatinine levels to assess renal safety during treatment with empagliflozin by standard clinical laboratory assay (mg/dL).

From baselinte to 12 months
Change in urinary albumin-to-creatinine ratio
Délai: From baseline to 12 months

Change in urinary albumin-to-creatinine ratio as a marker of renal damage and safety during empagliflozin treatment by standard urine laboratory testing (mg/g creatinine).

From baseline to 12 months
Change in serum electrolyte levels
Délai: From baseline to 12 months

Change in serum sodium and potassium levels to evaluate electrolyte safety during empagliflozin treatment by standard clinical laboratory testing (mmol/L).

From baseline to 12 months
Change in liver function tests
Délai: From baseline to 12 months

Change in alanine aminotransferase (ALT) and aspartate aminotransferase (AST) levels to assess hepatic safety by standard clinical laboratory assays (U/L).

From baseline to 12 months
Change in glycated hemoglobin (HbA1c)
Délai: From baseline to 12 months.

Change in HbA1c levels to monitor metabolic safety in non-diabetic CKD patients treated with empagliflozin by standard laboratory assay (%).

From baseline to 12 months.
Change in hematological parameters
Délai: From baseline to 12 months

Change in complete blood count parameters to evaluate hematological safety during treatment by standard clinical laboratory testing.

From baseline to 12 months
Change in blood pressure
Délai: From baseline to 12 months

Assessment of changes in both blood pressures (systolic and diastolic), by Standard sphygmomanometer measurement (mmHg).

From baseline to 12 months
Change in body weight
Délai: From baseline to 12 months

Change in body weight to assess tolerability and volume status during empagliflozin treatment by calibrated clinical scale (kg).

From baseline to 12 months
Discontinuation due to treatment intolerance
Délai: From baseline to 12 months

Number and proportion of participants who permanently discontinue empagliflozin due to treatment-related intolerance or adverse events. It will be achieved trough clinical visit records and adverse event reporting.

From baseline to 12 months

Collaborateurs et enquêteurs

C'est ici que vous trouverez les personnes et les organisations impliquées dans cette étude.

Parrainer

Les enquêteurs

  • Chercheur principal: Carlos Martínez Salgado, PhD, University of Salamanca
  • Chercheur principal: Pilar Fraile Gómez, MD, PhD, University of Salamanca

Dates d'enregistrement des études

Ces dates suivent la progression des dossiers d'étude et des soumissions de résultats sommaires à ClinicalTrials.gov. Les dossiers d'étude et les résultats rapportés sont examinés par la Bibliothèque nationale de médecine (NLM) pour s'assurer qu'ils répondent à des normes de contrôle de qualité spécifiques avant d'être publiés sur le site Web public.

Dates principales de l'étude

Début de l'étude (Réel)

1 avril 2026

Achèvement primaire (Estimé)

1 avril 2028

Achèvement de l'étude (Estimé)

1 décembre 2028

Dates d'inscription aux études

Première soumission

18 novembre 2025

Première soumission répondant aux critères de contrôle qualité

12 janvier 2026

Première publication (Réel)

16 janvier 2026

Mises à jour des dossiers d'étude

Dernière mise à jour publiée (Réel)

5 novembre 2026

Dernière mise à jour soumise répondant aux critères de contrôle qualité

4 novembre 2026

Dernière vérification

1 novembre 2026

Plus d'information

Termes liés à cette étude

Autres numéros d'identification d'étude

  • PI25/00053

Plan pour les données individuelles des participants (IPD)

Prévoyez-vous de partager les données individuelles des participants (DPI) ?

OUI

Description du régime IPD

Anonymized datasets and analytic code will be available upon reasonable request, following approval by the Ethics Committee and IBSAL data governance board.

Délai de partage IPD

Data will be available starting 12 months after publication of primary results and for a minimum of 5 years thereafter.

Critères d'accès au partage IPD

Qualified researchers with a methodologically sound proposal, as determined by the study steering committee, will be able to access the data. Requests should be directed to the study PI. A data access agreement will be required.

Type d'informations de prise en charge du partage d'IPD

  • PROTOCOLE D'ÉTUDE
  • SÈVE
  • ANALYTIC_CODE

Informations sur les médicaments et les dispositifs, documents d'étude

Étudie un produit pharmaceutique réglementé par la FDA américaine

Non

Étudie un produit d'appareil réglementé par la FDA américaine

Non

Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .